Olaparib combo improves PFS in metastatic prostate cancer Olaparib combo improves PFS in metastatic prostate cancer
Frontline olaparib plus abiraterone/prednisone combo improves survival in patients with metastatic castration-resistant prostate cancer.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Change in Cardiorespiratory Fitness Linked to Prostate Cancer Incidence
WEDNESDAY, Jan. 31, 2024 -- Change in cardiorespiratory fitness (CRF) is inversely associated with the risk for prostate cancer incidence, but not mortality, according to a study published online Jan. 30 in the British Journal of Sports... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2024 Category: Pharmaceuticals Source Type: news
Just a Small Boost in Fitness Cuts Men's Prostate Cancer Risk
WEDNESDAY, Jan. 31, 2024 -- Even small increases in a man’s cardio fitness can significantly reduce his risk of developing prostate cancer, researchers report.
An annual increase in aerobic fitness of 3% or more is linked to a 35% lower risk... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 31, 2024 Category: General Medicine Source Type: news
PSMA-PET helps plan treatment in men with relapsed prostate cancer
This study is an interim analysis on the use of PSMA-PET for managing patients, while the final readout of the primary endpoint -- whether the technique improves outcomes -- is planned for 2025, they noted.
The researchers included a total of 178 with salvage RT plans available who had enrolled in the trial between September 2018 and August 2020 at UCLA and the University of California, San Francisco. They split 76 patients into a control arm and 102 to the PSMA-PET arm; fluciclovine-PET was used in 33 patients in the control arm.
The main management change observed in the PSMA-PET arm was treatment escalation (addition ...
Source: AuntMinnie.com Headlines - January 31, 2024 Category: Radiology Authors: Will Morton Tags: Radiation Oncology/Therapy Source Type: news
Men can slash their odds of getting prostate cancer by a THIRD through simple lifestyle tweak
Prostate cancer is the most common cancer in men in the UK with 1 in 8 men being diagnosed with prostate cancer in their lifetime. (Source: the Mail online | Health)
Source: the Mail online | Health - January 30, 2024 Category: Consumer Health News Source Type: news
Getting fitter can reduce prostate cancer risk by 35%, study finds
Increase in cardiorespiratory levels of 3% annually found to be beneficial, Swedish research suggestsMen can reduce their risk of prostate cancer by as much as 35% by doing a little more jogging, cycling or swimming, a study suggests.Boosting cardiorespiratory fitness by only 3% over the course of a year was linked to a much lower chance of developing the disease. The findings prompted the researchers to encourage men to boost their fitness levels to help cut their prostate cancer risk.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - January 30, 2024 Category: Science Authors: Andrew Gregory Health editor Tags: Prostate cancer Fitness Health Medical research Sweden UK news Source Type: news
Bot Image highlights performance of ProstatID in study
AI medical device company Bot Image is highlighting the performance of its ProstatID in a study evaluating its ability to detect, diagnose, and screen for prostate cancer.
The device, which has clearance by the U.S. Food and Drug Administration (FDA), evaluated biparametric MR images and achieved an area under the curve (AUC) of 0.936. The study saw 13 board-certified abdominal radiologists reading the same prostate MR image sets with confirmed biological ground truth points. Compared with the device, they achieved an AUC of 0.742.
Bot Image further highlighted that the results show how ProstatID can aid in early detecti...
Source: AuntMinnie.com Headlines - January 30, 2024 Category: Radiology Authors: AuntMinnie.com staff writers Tags: Industry News Source Type: news
A plasma membrane –associated form of the androgen receptor enhances nuclear androgen signaling in osteoblasts and prostate cancer cells | Science Signaling
Androgen receptor signaling at the membrane augments nuclear responses to androgens in two different cell types. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - January 30, 2024 Category: Science Source Type: news
More Side Effects With Local Therapies for Prostate Cancer More Side Effects With Local Therapies for Prostate Cancer
Local therapies for advanced prostate cancer were associated with significantly more gastrointestinal and sexual issues in subsequent years than systemic treatments.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2024 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news
Zydus launches pill for prostate cancer patients
The drug firm said the medication would cost Rs 6,995 per month, which is 50 per cent less than the currently available injectable options. "With this, the treatment for prostate cancer in India can now be made completely oral, thus helping patients lead a better quality of life," Zydus Lifesciences said in a regulatory filing. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - January 30, 2024 Category: Pharmaceuticals Source Type: news
Defense Secretary Lloyd Austin returns to work at the Pentagon after cancer surgery complications
Defense Secretary Lloyd Austin has returned to work at the Pentagon after nearly a month’s absence because of prostate cancer (Source: ABC News: Health)
Source: ABC News: Health - January 29, 2024 Category: Consumer Health News Tags: Health Source Type: news
Treatment Adverse Events Vary With Favorable, Unfavorable Prognosis in Prostate Cancer
MONDAY, Jan. 29, 2024 -- For patients with localized prostate cancer, the rates of adverse outcomes associated with specific treatments vary for favorable- and unfavorable-prognosis disease, according to a study published online in the Jan. 23/30... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2024 Category: Pharmaceuticals Source Type: news
The cancers that doctors don't want to call cancers... because the word is 'too scary'
Low-grade prostate cancers that grow very slowly should not be called cancer or carcinoma, doctors have suggested. It can scare men and even their doctors into more aggressive treatment. (Source: the Mail online | Health)
Source: the Mail online | Health - January 29, 2024 Category: Consumer Health News Source Type: news
Defense Secretary Has'Excellent' Prognosis After Prostate Cancer Treatment, Docs Say
MONDAY, Jan. 29, 2024 -- Defense Secretary Lloyd Austin will not need any more treatment for his prostate cancer and his prognosis is " excellent, " his doctors say.The news came after a follow-up appointment Austin had at Walter Reed National... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 29, 2024 Category: General Medicine Source Type: news
More Evidence That ARSIs for Prostate Cancer Differ in Cognitive Effects
(MedPage Today) -- SAN FRANCISCO -- Two widely used androgen receptor signaling inhibitors (ARSIs) had a similar overall effect on cognitive function in men with metastatic castration-resistant prostate cancer (mCRPC) but differed significantly... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news
